News | EP Lab | May 19, 2020

Thermedical SERF Ablation System Earns FDA Breakthrough Device Designation 

Saline enhanced radiofrequency thermal-ablation designed to treat ventricular tachycardia

Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.

May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter. The FDA Breakthrough Devices Program is intended to help patients receive more timely access to technologies that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.  

Ventricular tachycardia, which is an abnormally rapid heart rhythm, is a leading cause of sudden cardiac death worldwide. Sudden cardiac death kills 325,000 U.S. adults annually, more than any other natural cause.

“Today, an estimated 1 million people who develop, or are likely to develop VT annually, have limited options for effective treatment and often suffer a very poor quality of life,” said Roy Tanaka, member of Thermedical’s board of directors. “Thermedical’s ablation technology will be transformational in clinical electrophysiology. It offers the potential for an entirely new therapy that could replace the standard-of-care treatment for VT.” 

Implantable cardioverter defibrillators (ICD) constantly monitor a patient’s heart rhythm and are the current treatment for patients suffering from VT. However, this approach does not stop the progression of the disease or provide a cure. In addition, ICDs can be costly and painful. During a VT episode, the ICD delivers energy to the heart muscle via a powerful shock or antitachycardia pacing to help the heart beat normally again. Today, VT patients with ICDs and who experience persistent VT episodes may be treated with conventional RF ablation – a lengthy procedure with a moderate success rate of approximately 50 percent.[1] 

Thermedical’s SERF ablation system provides a new form of biological heat transfer that is 20 times more effective at transferring heat than conventional ablation methods. Compared to conventional VT ablation catheters, the Durablate catheter can accurately control the ablation size and treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias that cause VT are often located. 

“Preliminary results are encouraging. I am optimistic that this therapy will offer new hope for patients with VT who have failed all other therapeutic options,” explained  William G. Stevenson, M.D., professor of medicine at Vanderbilt University Medical Center, and a principal investigator in the SERF VT Early Feasibility Study (EFS).

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT. The trial is underway in the U.S. and Canada.

“We are pleased to have the FDA recognize the novelty and potential for our therapeutic approach in treating VT as a breakthrough technology and look forward to a continued productive relationship with FDA to expedite access to patients who have few to no therapeutic options,” said Trena Depel, vice president of clinical, regulatory and quality at Thermedical.

Thermedical is a privately held company founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni, Michael G. Curley, Ph.D. and Patrick S. Hamilton, Ph.D., based in Waltham, Mass. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH* Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the company has developed thermal-ablation systems to treat VT and solid tumors. 

Read more abourt this technology from the 2020 Heart Rhythm Society (HRS) late-breaking session — Saline Enhanced Radiofrequency Ablation May be an Effective Method to Treat Ventricular Tachycardia.
 

For more information: www.thermedical.com

 

Reference:

1. Andre d’Avila, Sheldon M. Singh. Ventricular Tachycardia Ablation Are We Winning the Battle But Losing the War? JACC. Vol. 67, No. 6, 2016. doi.org/10.1016/j.jacc.2015.10.095.
 

 

 

 

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve